A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

PHASE3CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

December 27, 2022

Study Completion Date

December 27, 2022

Conditions
ObesityOverweightMetabolism and Nutrition Disorder
Interventions
DRUG

Tirzepatide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (29)

102202

Beijing Tsinghua Changgung Hospital, Beijing

136000

Siping Central People's Hospital, Siping

150001

The Fourth Affiliated Hospital of Harbin Medical University, Harbin

200032

Zhongshan Hospital, Fudan University, Shanghai

200040

Huadong Hospital Affiliated to Fudan University, Shanghai

200071

Shanghai Hospital of Traditional Chinese Medicine, Shanghai

200240

The Fifth People's Hospital of Shanghai, Shanghai

201199

Shanghai Minhang District Central Hospital, Shanghai

201700

Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai

210011

The Second Affiliated Hospital of Nanjing Medical University, Nanjing

211100

Nanjing Medical University - Nanjing Jiangning Hospital, Nanjing

213000

Changzhou No.2 People's Hospital, Changzhou

214023

Wuxi People's Hospital, Wuxi

226001

Affiliated Hospital of Nantong University, Nantong

250013

Jinan Central Hospital, Jinan

300052

Tianjin Medical University General Hospital, Tianjin

310006

The First People's Hospital of Hangzhou, Hangzhou

313000

Huzhou Central Hospital, Huzhou

315010

Ningbo First Hospital, Ningbo

400016

The First Affiliated Hospital Chongqing Medical University, Chongqing

421001

The First Affiliated Hospital of Nanhua University, Hengyang

450014

The Second Affiliated Hospital of Zhengzhou University, Zhengzhou

471003

The First Affiliated Hospital of Henan University of Science &Technology, Luoyang

510280

Zhujiang Hospital, Guangzhou

518039

Shenzhen Second People's Hospital, Shenzhen

610041

West China Hospital of Sichuan University, Chengdu

710077

The First Affiliated Hospital of Xi'an Medical University, Xi’an

066000

The First Hospital of Qinhuangdao, Qinhuangdao

Unknown

The Second Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT05024032 - A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) | Biotech Hunter | Biotech Hunter